AI mole checker tested at home – but trial stops early

NCT ID NCT05321784

Terminated Diagnosis Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a device called the Sklip System, which uses artificial intelligence, could help people at home decide if a mole might be skin cancer. Only one person took part before the study was stopped early. The goal was to see if the AI could match or beat standard methods for spotting cancers like melanoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sklip System (AI-powered dermoscopy device)
What this could lead to: If successful, this could allow people to safely check their own moles at home for skin cancer, reducing unnecessary doctor visits.
What could go wrong: The trial was terminated early with only 1 participant, so no reliable conclusions can be drawn. The technology may not be accurate enough for home use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL MELANOCYTIC NEVI WITH UNCERTAIN MALIGNANT POTENTIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma melanoma neutrophil actin dysfunction skin cancer skin neoplasm squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SKIN NEOPLASM

Contacts and locations

Locations

OHSU Knight Cancer Institute

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.